Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.
 

Share

    


In This Section

Home / News & Media / News Template
Press Release Logo  
 

CONTACT:
Lori Gardner, Senior Director
Membership and Public Relations
301.984.9496 ext. 226


FOR IMMEDIATE RELEASE: Aug 01, 2016


ACCC Honored to Contribute to National Academies Immunotherapy Policy Workshop Proceedings

Statement from ACCC President Jennie R. Crews, MD, MMM, FACP

Recent advances in immunotherapy have launched an exciting new era for cancer treatment. However, to expand patient access to these groundbreaking therapies the oncology community must overcome evolving implementation and policy challenges. In support of efforts to identify and address these emerging issues, Association of Community Cancer Centers (ACCC) joined with other invited participants in a workshop on Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment convened by the National Cancer Policy Forum of the National Academies of Sciences, Engineering, and Medicine.* Participants examined state-of-the-science clinical challenges and policy issues around these promising new therapies.

Representatives from the Institute for Clinical Immuno-Oncology (ICLIO), an institute of ACCC, were honored to join with representatives from the research, clinician, patient, government agency, pharmaceutical industry, and healthcare payer communities—all united in an effort to bring forward understanding of challenges to realizing the potential of these new therapies.

As reported in the workshop proceedings, Lee Schwartzberg, MD, FACP, Chair of the ICLIO Advisory Committee, brings to light critical educational challenges clinicians are facing in adopting these new therapies, including lack of information about specific therapies, few experts to consult with, and a lack of immunotherapy education and training for their staff and peers. ICLIO’s vital role in helping to close these educational gaps for all members of the multidisciplinary care teams providing immunotherapy in the community was also noted.

As we work to bring immunotherapy to patients close in their home communities, ACCC and the Institute for Clinical Immuno-Oncology look forward to continued collaboration with all stakeholders in advancing quality, patient-centered cancer care.

*In March 2016, the Institute of Medicine (IOM) was renamed the National Academies of Sciences, Engineering, and Medicine (the Academies) Health and Medicine Division (HMD).


About the Association of Community Cancer Centers


The Association of Community Cancer Centers (ACCC) is the leading education and advocacy organization for the cancer care community. Founded in 1974, ACCC is a powerful network of 25,000 multidisciplinary practitioners from 2,100 hospitals and practices nationwide. As advances in cancer screening and diagnosis, treatment options, and care delivery models continue to evolve — so has ACCC — adapting its resources to meet the changing needs of the entire oncology care team. For more information, visit accc-cancer.org or call 301.984.9496. Follow us on Facebook, Twitter, and LinkedIn; read our blog, ACCCBuzz; and tune in to our podcast, CANCER BUZZ.